Featured Writers

      By Sheri Colberg, Ph.D., FACSM       Over the years, I have had many exercisers with diabetes ask me why they’re gaining weight instead of losing it. There are two possible answers to that question.

The American College of Sports Medicine and the American Diabetes Association: joint position statement    By Sheri Colberg, Ph.D., FACSM, Committee Chairperson   In the midst of the latest gloomy projections on the rapidly expanding worldwide rates of diabetes mellitus, the latest research on physical activity — reported in a …

CYCLOSET is the first in-class and only centrally acting dopamine agonist oral antidiabetic. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in …

SF: Can you give an example of how the error reporting works? KT: I have attached a NCPS Alert (in pdf format) from March 2009 on U 500 Insulin. This was the specific incident: “South West VA CMOP received an order for 40 units of U-500 insulin and questioned its …

SF: What are the most common errors that occur at the VA in regards to diabetes patients and what has the VA done to prevent them from happening again? KT: The data found within NCPS SPOT data is voluntarily reported so it is not a good indicator for prevalence of …

SF: How do you minimize errors? KT: Here is some more background to better understand the basis of our program. Neither the VA nor any other health care system can or will ever be able to “eliminate all errors.” Patient safety programs focused exclusively on eliminating errors will fail….

SF: What is the VA’s NCPS doing to change the medical safety culture so medical professionals will report all errors not just the ones that cause harm? KT: We developed a confidential reporting system that allows VA caregivers to report not only adverse events, but close calls. The NCPS staff …

By Sheri Colberg, PhD   As if the predictions of diabetes to come were not already grim enough, a new report released by the Centers for Disease Control and Prevention (CDC) now predict that one in three American adults may have diabetes by 2050, with the number of diabetes patients …

By Iriny Nashed, PharmD Candidate Just when we thought we had it all figured out when it comes to diabetes management, we find there are not only new drugs on the horizon but new classes of medications that might just change the entire outlook on diabetes treatments.

  OVERVIEW: Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. The company recently submitted a New Drug Application to the …